Skip to content
ApprovedFDA approvedATC · Not yet assigned (not yet in the WHO ATC index)Rx · Prescription only (Rx); FDA-approved 2026 (Foundayo)

Orforglipron (LY3502970)

Prescription weight-loss GLP-1 medicine for obesity and overweight: taken by mouth, an alternative to injectable drugs.

Orforglipron (LY3502970) vial

DETAILED OVERVIEW

What is Orforglipron (LY3502970)?

Orforglipron is Eli Lilly's prescription medicine for long-term weight management, taken by mouth as an alternative to injections. The FDA approved it in April 2026 as Foundayo for obesity, or for overweight with at least one weight-related condition, alongside diet and exercise. It is not yet approved for diabetes or in Europe.

It mimics the gut hormone GLP-1: it lowers appetite, slows how fast the stomach empties and, depending on blood sugar, makes the body release more insulin. It is a small organic molecule, so the stomach does not break it down. In human studies it produced substantial weight loss. The most common side effects are digestive (nausea, vomiting, diarrhoea), mainly at the start of treatment; inflammation of the pancreas can occur rarely. In rodents drugs of this class caused thyroid tumours, so the FDA requires a prominent warning, and it must not be given to anyone with a personal or family history of medullary thyroid cancer.

ATC code

None yet (not in the WHO ATC index)

Prescription

Prescription only (Rx), FDA 2026 (Foundayo)

Mechanism

Oral small-molecule GLP-1 receptor agonist

Half-life

29-49 h (once-daily dosing)

Onset

Tmax 4-8 h; full weight effect over months

Data console

Lab data

ATC codeNot yet assigned (not yet in the WHO ATC index)
PrescriptionPrescription only (Rx); FDA-approved 2026 (Foundayo)
MechanismOral small-molecule GLP-1 receptor agonist: by binding the…
Half-life~29-49 hours (once-daily dosing reaches steady-state in 7-10 days)
OnsetTmax 4-8 h (peak plasma); the full weight-lowering effect develops over months
Bioavailability~77% (oral, absolute – FDA Foundayo label); the long half-life allows once-daily dosing

Safety

Side effects, stop signs, contraindications

Side effects · 7

  • Gastrointestinal effects (nausea, vomiting, diarrhea, abdominal discomfort), especially during dose titration; these are dose-dependent and the most common adverse events, though with somewhat lower incidence than injectable peptide GLP-1 RAs.
  • Decreased appetite and early satiety with associated weight loss; this is partly mechanism-related but can also lead to unwanted degree of weight and lean-mass loss.
  • Risk of hypoglycemia when combined with insulin or a sulfonylurea (on its own the GLP-1 RA glucose-dependent action makes hypoglycemia risk low).
  • Headache, fatigue, and dizziness in the early phase of treatment.
  • Acute pancreatitis is a rare but potentially serious risk, as with GLP-1 receptor agonists generally; persistent, severe abdominal pain radiating to the back requires immediate medical evaluation.
  • Gallbladder disease (gallstones, acute cholecystitis), which may be related both to rapid weight loss and to the GLP-1 effect.
  • Marked fullness, reflux, and occasionally altered absorption of orally taken medicines due to slowed gastric emptying.

Contraindications · 3

  • History of medullary thyroid carcinoma (MEN-2 syndrome) – class effect for all GLP-1 RAs
  • History of pancreatitis (relative)
  • Severe gastroparesis

Studies

Related research and clinical findings

Telegram

Have a question about Orforglipron (LY3502970)?

Educational drug info from official sources (PubMed, FDA, EMA). Does NOT replace medical consultation or the SmPC. Talk to your doctor!

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 13, 2026

The information here is for educational and scientific purposes only. Medication use requires medical consultation and a prescription. The indications, dose ranges, and side effects listed here do NOT replace the official Summary of Product Characteristics (SmPC) or consultation with a physician. Do not start or stop any medication on your own. In an emergency, call your local emergency number.